**Table 1.** Dynamics summary of study characteristics

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Summary Characteristic | WHO region |  |  |  |  |  |  |
|  | African | Region of the Americas | Eastern Mediterranean | European | Southeast Asia | Western Pacific | Total |
| Outbreak years | 2001-2019 | 2015-2018 | 2004-2017 | 2004-2008 | 2000-2019 | 2008-2022 | 2000-2022 |
| Number of countries reporting outbreaks | 7 | 2 | 3 | 2 | 5 | 2 | 21 |
| Number of outbreaks | 19 | 2 | 3 | 2 | 9 | 3 | 38 |
| Median duration weeks (range) | 23 (3-143) | 27 (10-44) | 10 (9-58) | 1.5 (1-2) | 9 (3-104) | 19 (6-209) | 19 (1-209) |
| Median time to peak weeks (range) | 8 (2-122) | 7 (2-12) | 6 (4-26) | 1 (1-1) | 4 (2-63) | 17 (4-122) | 7 (1-122) |
| Number of multidrug resistant (MDR)\* | 9 | - | 1 | 1 | 2 | - | 13 |
| Number of Extremely drug resistant (XDR)\*\*! | - | - | 1 | - | - | 1 | 3 |
| Total number of suspected cases | 29142 | 148 | 856 | 643 | 7054 | 1819 | 39662 |
| Median suspected cases (range) | 860 (10-10230) | 74 (38-110) | 187 (83-586) | 322(6-637) | 79(9-5963) | 31(23-1765) | 396 (6-10230) |
| Total number of confirmed cases | 672 | 91 | 584 | 95 | 832 | 1630 | 3904 |
| Median confirmed cases (range) | 36.5 (5-191) | 45.5 (25-66) | 74 (24-486) | 47.5 (4-91) | 51 (2-288) | 25 (23-1582) | 46 (2-1582) |

Table 1. Dynamics summary of study characteristics

\*MDR: defined as resistant to chloramphenicol, ampicillin (penicillin), and trimethoprim-sulfamethoxazole

\*\*XDR: defined as resistant to chloramphenicol, ampicillin (penicillin), and trimethoprim-sulfamethoxazole, along with fluoroquinolones and third-generation cephalosporins.

!XDR outbreak occurred in Pakistan and China